title: Current and future trials of the EORTC brain tumor group.
abstract: The EORTC Brain Tumor Group (BTG) is dedicated to clinical research of neoplasms of the brain. In the past years the BTG has carried out phase II and phase III trials on glial tumors, brain metastases and primary CNS lymphomas. Future studies will investigate novel drugs in combination with chemo-radiotherapy in glioblastoma multiforme, radiotherapy in meningioma, and chemotherapy in medulloblastoma. The BTG will also start a new phase III trial on newly diagnosed low-grade glioma comparing radiotherapy to temozolomide. In all our trials translational research is getting more and more important, often this is one of the most important ways to get useful conclusions from clinical trials. The wide recognition of the importance of translational research for clinical trials and in particular with targeted therapies implies that this type of research will become a mandatory element in many of our future trials.
authors.affiliation: Department of Neuro-Oncology/Neurology Daniel den Hoed Cancer Center/Erasmus Medical Center, Rotterdam, The Netherlands. m.vandenbent@erasmusmc.nl
authors.forename: M J
authors.initials: MJ
authors.lastname: van den Bent
authors.forename: R
authors.initials: R
authors.lastname: Stupp
authors.forename: A A
authors.initials: AA
authors.lastname: Brandes
authors.forename: D
authors.initials: D
authors.lastname: Lacombe
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D002986:Clinical Trials as Topic / Q000379:methods* / Q000639:trends*; D003131:Combined Modality Therapy; D005062:European Union; D005910:Glioma / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans
chemical_list: D000970:Antineoplastic Agents